Finally, the positive results of inhibiting IFN-γ in primary HLH may provide a solid rationale to arrange further clinical studies, paving the way towards new therapeutic targets and reducing the high mortality rate in MAS during AOSD. The gene discussed is IFNG; the disease is adult-onset Still disease.